2022
Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study
Howell J, Samani A, Mannan B, Hajiev S, Aval L, Abdelmalak R, Tam VC, Bettinger D, Thimme R, Taddei TH, Kaplan DE, Seidensticker M, Sharma R. Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study. Therapeutic Advances In Gastroenterology 2022, 15: 17562848221100106. PMID: 36199289, PMCID: PMC9527996, DOI: 10.1177/17562848221100106.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseImpact of NAFLDBody mass indexOverall survivalHepatocellular carcinomaLiver diseasePresence of NAFLDMultivariable Cox proportional hazardsMedian body mass indexAdvanced-stage hepatocellular carcinomaGrade 2 hypertensionLower starting doseInternational cohort studySimilar clinical benefitsFatty liver diseaseStage hepatocellular carcinomaCox proportional hazardsLogistic regression modellingStarting doseAdverse eventsCohort studyPrognostic factorsClinical outcomesMass indexClinical benefit
2013
Carvedilol for preventing recurrent variceal bleeding: Waiting for convincing evidence
Bosch J, Groszmann R, Iwakiri Y, Taddei T. Carvedilol for preventing recurrent variceal bleeding: Waiting for convincing evidence. Hepatology 2013, 57: 1665-1667. PMID: 23359118, DOI: 10.1002/hep.26279.Peer-Reviewed Original ResearchCarvedilol groupSevere adverse eventsVariceal bleedingAdverse eventsVariceal rebleedingRecurrent bleedingI groupControl of acute esophageal variceal bleedingPrevention of gastroesophageal variceal rebleedingPreventing recurrent variceal bleedingAcute esophageal variceal bleedingDecrease portal pressureRecurrent upper gastrointestinal bleedingRecurrent variceal bleedingEsophageal variceal bleedingUpper gastrointestinal bleedingMedian followEsophageal varicesGastric varicesPortal pressureGastrointestinal bleedingIsosorbide mononitrateBleedingCarvedilolPatients